These benefits were observed in both diabetic and non-diabetic participants, suggesting a broad metabolic effect rather than glucose-dependent changes
Rybelsus is also an oral semaglutide product, but it is licensed for type 2 diabetes management, not weight loss, and uses a different dosing schedule
Collectively, these signals indicate that additional regulatory guidance or policy refinement may be forthcoming as the Agency continues to assess safety, quality, and appropriate use within this category (FDA, 2024)
Research gaps and future directions for SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease SGLT2, sodium-glucose cotransporter 2
Trusted Medications and Expert Support By choosing Klinic, you benefit from premium support with a focus on FDA-approved branded medications only